Evommune EVMN Cash Flow Statement (2024-2026)

NYSE EVMN
$12.41 +0.41 (+3.42%)
As of: Sep 4, 2026 · 1:50 PM EDT
Reported Financials

Evommune Quarterly Cash Flow Statement

Periods 8 quarters
Latest Jun 2026

Evommune reported cash from operations of -$20.32M and free cash flow of -$20.50M for the quarter ended Jun 2026, up 22.5% year over year. This cash flow statement covers 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -15.92M-20.73M-14.43M-22.62M-12.47M-28.27M-21.67M-32.25M
Share-based CompensationStock Comp. 0.40M5.50M0.54M0.56M3.75M4.20M6.68M7.48M
Cash from OperationsCash from Ops. -18.51M-23.90M-26.21M-9.63M-16.70M-27.50M-20.32M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles 0.45M0.42M0.25M0.51M0.58M0.79M0.76M
Depreciation & Amortization (CF)Dep. & Amort. 0.36M0.38M0.38M0.31M0.33M0.35M0.55M
Change in Working Capital
Change in Account PayablesChange Payables 2.85M-0.69M-3.90M-0.10M3.85M-3.75M0.98M
Change in Accured ExpensesChange Accured Exp. -0.14M-2.10M1.29M-0.67M4.30M-4.81M5.95M
Other Working Capital ChangesOther WC Changes -3.00M
Investing Activities
Capital ExpendituresCapex 0.13M0.10M0.08M0.18M
Change in Acquisitions & DivestmentsChange Acquisitions 11.50M13.50M18.00M15.00M37.60M23.50M49.12M
Cash from Investing ActivitiesCash from Investing -33.08M13.50M18.00M-23.91M-122.90M-85.36M31.29M
Financing Activities
Other financing activitiesOther financing 0.01M0.00M0.73M0.14M156.41M117.20M-0.06M
Cash from Financing ActivitiesCash from Financing 49.70M-0.15M64.34M-0.27M156.85M117.11M0.53M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued 1.48M2.89M0.01M
Additional items
Change in Cash -1.89M-10.55M56.13M-33.81M17.25M4.25M11.51M
Free Cash FlowFCF -18.51M-23.90M-26.21M-9.77M-16.80M-27.59M-20.50M
Net Cash FlowNCF -1.89M-10.55M56.13M-33.81M17.25M4.25M11.51M